The strategy during a pandemic is to go into these decisions knowing that you're at risk, that some, or even all, of the vaccine platforms might not pan out. The reason for procuring, or recommending to procure, different platforms is that any one, or two, or maybe even three of those platforms, when they move into clinical trials, might not be safe, or they might not be effective. Therefore, we recommended really over-procurement, knowing that maybe only one would work, in which case we would have enough for every Canadian to be vaccinated adequately.
From the very beginning, there was always discussion that given that we were potentially in a situation of having too many vaccines, we would want to use those for the benefit of others. That was always part of the thinking, but it was difficult to say that back in June, because we had no idea that we would be in a situation where so many have succeeded.